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ABSTRACT	
	
Aim: To evaluate the influence of chemotherapy agents and their accessories on oral manifestations of children 
who have acute lymphoid leukemia. 
Material	 and	 Methods: After the stipulated period for the research, the total sample reached was of 
68children. Nevertheless, only 46 children had continued for the second period. Children from 2 to 12 years of 
age who had been diagnosed with ALL – and would be submitted to treatment at Ophir Loyola Hospital, in 
Belém, State of Pará – had been included in the research. The first evaluation has been held before the 
chemotherapy treatment and had offered anamnesis and clinical exams. The second evaluation has been held 
in 10 to 15 days after the beginning of chemotherapy treatment and has offered a new clinical exam and 
annotations of the drugs which had been utilized during the chemotherapy. 
Results: From the drugs given at Ophir Loyola Hospital, it has been observed that 14 to 24mg (83%), vincristine 
0,6mg to 1 g (80%), ARA-C 20mg to 1600mg (74%), cardioxane13mg to 340mg (65%), methotrexate   12mg to 
2400mg (63%), cyclophosphamide 104mg to 1540mg (59%), asparaginase 50UI to 9600UI (57%) andmesna 75mg 
to 510mg (54%)  have been used the most. No drug has presented statistic at 5% levelin Fisher exact test, when 
crossing with the presence of the main mouth manifestations: mucositis, xerostomia, toothache,and 
dysphagia. 
Conclusions: In the face of the results, it can be concluded that there has been no influence of the 
chemotherapy agents and their accessories in the oral manifestations of acute lymphoid leukemic children; 
nevertheless, these patients may present any kind of lesion on the mouth cavity during or after the beginning 
of chemotherapy. The dental surgeon needs to recognize the oral manifestations and intervene on the buccal 
health of the ALL patients, contributing and helping with his/her treatment. 
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INTRODUCTION 
 Acute lymphoid leukemia (ALL) 
affects around 80% of leukemia, and it 
occurs in most cases with children1.ALL is 
a result of an excessive and uncontrolled 
production of blasts of the lymphoid 
kind, making the normal production of 
red and white blood corpuscles, as well as 
blood platelets. The chances of survival 
had increased with the advance in the 
types of anti-neoplastic treatment2,3. 
 The chemotherapy drugs act 
s y s t e m a t i c a l l y o n t h e c e l l l e v e l , 
specifically on the cells with a cell 
division process, interfering with its 
growth and division1. During the anti-
neoplastic treatment, the buccal lesions 
become even more intense, for the 
chemotherapy treatment acts on little-
differentiated cells, or with a high 
metabolism rate, which affects beyond 
the blastic and normal organism cells3. 
 Having this exposed, our goal is 
t o e v a l u a t e t h e i n f l u e n c e o f 
c h e m o t h e r a p y a g e n t s a n d t h e i r 
accessories on the oral manifestations of 
children affected by acute lymphoid 
leukemia. 
MATERIAL AND METHODS 
 T h i s r e s e a r c h h a s b e e n 
submitted to the evaluation of the Ethics 
Committee of Research with Human 
Beings, through the Cruzeiro do Sul 
University Ethics Committee, which has 
approved it with protocol number CE/
UCS-005/2014. 
 The legal tutors of the selected 
children had been clarified and informed 
about the research; the ones who, after 
reading the Informed Consent Form– 
ICF – had agreed with the participation 
of their child, had signed the paper. 
 The final sample of this study 
has been constituted of 46 children who 
had been enrolled/attended at Ophir 
Loyola Hospital (OLH), a reference to the 
cancer treatment of the public service in 
the State ofPará. Convenience sample has 
been adopted, one cancer in children and 
teenagers is a rare condition, which 
corresponds to about 3% of all malign 
tumors in most of the populations (OMS, 
1997). 
 The criteria of inclusion that has 
been used was the inclusion of children 
affected with acute lymphoid leukemia – 
ALL, who had been submitted to anti-
neoplastic treatment, with chemotherapy 
from ages 2 to 12 years old; both genders, 
independently of the skin color or social 
and economic conditions, all residents of 
the State of Pará. 
 In order to diminish the 
variability of inter-examiner diagnosis 
and higher the reliability of the data 
identified, a training and calibration 
have been held previously at the 
beginning of the exams.The agreement 
of inter-examiner diagnosis was of 0.78, 
which has been considered a good rate. 
 The data collection had been 
performed in two stages: The first one 
after the receiving of the cancer 
diagnosis and before the anti-neoplastic 
treatment and it has been done with 
anamnesis and clinical exam. In the 
second stage, approximately 10 to15 days 
after the beginning of the anti-neoplastic 
treatment, a new clinical exam has been 
done and there have been annotations of 
drugs that had been used during 
chemotherapy. 
RESULTS 
 All examined children were doing 
the first cycle of chemotherapy. 
Nevertheless, the frequency of a number 
of sessions done by the second stage of 
the research has been evaluated, as figure 
1 shows. 
 T h e n u m b e r o f t y p i c a l 
chemotherapy sessions (trend) was of 
four, which is also the average of this 
distribution, having a minimum of one 
session and a maximum of nine. The 
interquartile interval varies from two to 
six sessions. 
Figure 1. Number of chemotherapy sessions of 
children from the sample. 
 Chemotherapy is a treatment that 
uses medication to destroy sick cells. The 
drugs given atOLHare the ones that 
follow on figure 2. It has been observed 
that daunorubicin 14 to 24mg (83%), 
vincristine 0.6mg to 1 g (80%), ARA-C 
20mg to 1600mg (74%), cardioxane 13mg 
to 340mg (65%), methotrexate 12mg to 
2400mg (63%), cyclophosphamide 104mg 
to 1540mg (59%), asparaginase 50UI to 
9600UI (57%) and mesna 75mg to 510mg 
(54%)  were the most used ones. It is 
important to note that the drugs 
cardioxane and mesna are accessories to 
the chemotherapy treatment. 
 Table 1 summarizes the analysis of 
the possible influence of drugs on buccal 
alterations. The 32 contingency tables are 
disposed on the table with drugs in the 
columns and the types of buccal 
alterations in the group of lines. The lines 
named “%” are the ones that present 
percentages of each factor to its 
respective column. The lines named “Χ²” 
present the chi-square statistic calculus 
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for each table of contingency. The lines 
nominated “p-valor” (p-value) present the 
p-value taking into consideration the 
number of degrees of freedom of the 
corresponding contingency. 
Figure 2. Drugs used for children’s treatment. The 
six superior bars nominate the accessory drugs. 
 Because Fisher’s exact test had 
been used, the chi-square statistic value 
has been left blank, for, in this case, the 
p-value is calculated without this 
statistic. 
 None of the contingency tables 
above present statistical significance on 
the level of 5%, or, explaining in another 
way, in the level of 5% in none of the 
c o n t i n g e n c y t a b l e s a b o v e t h e 
independency null hypothesis can be 
discarded among the category variables 
of each crossing of each table. 
DISCUSSION 
 C h e m o t h e r a p y i s u s u a l l y 
composed by liquid medication that is 
mixed into the saline solution and 
injected into the patient. Each session 
lasts about one hour. The session 
numbers vary according to the patient, 
but they are generally an average of six to 
eight applications. The time interval 
between them is also variable, but it is of 
usually of 21 days (THOMAZ et al., 2013). 
In this research, the average of sessions 
has been of 4.63. Nevertheless, 9 patients 
had made 6 sessions, 1 had made 7 
sessions and 6 had made 8 sessions. 
Subramaniam, Babu & Nagarathna 
(2008) and Torres, et al. (2010) had 
evaluated the oral manifestations in 
c h i l d r e n w i t h A L L d u r i n g t h e 
chemotherapy process. They had 
performed intraoral exams after the 
f o u r t h a n d t h e t h i r d s e s s i o n s , 
respectively. 
 The possible collateral effects of 
chemotherapy are countless. Morais et al. 
(2014) had identified that among the 
m o s t u n c o m f o r t a b l e s y m p t o m s 
according to the children in treatment, 
there are: nausea and vomiting, weight 
gain, pain, hypersensitiveness reaction, 
fatigue, and fever. These symptoms 
interfere directly in their daily lives, 
causing them to have the state of well-
being diminished and, consequently, a 
worsening of the life quality. 
 For many times this is the 
moment when the child or the teenager 
notices himself/herself as truly sick, 
which is aggravated by the restricted 
periods of hospitalization, as well as 
home stays. This makes them experiment 
the process in a more difficult way. 
Table 1. Frequency of the different buccal alterations according to drugs used in chemotherapy.  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 When searching for literature 
about the drugs used during the 
chemotherapy treatment for ALL, it could 
have been noticed the lack of agreement, 
as well as the scarcity about the subject. 
Pinto et al. (2006) had detected that the 
protocol used for the treatment of acute 
leukemia has been proposed by the 
Brazilian Society of Pediatric Oncology, 
and methotrexate is one of the most used 
drugs in this therapy. Chlorhexidine 
gluconate 0.12% has been administered 
for 10 consecutive days, after each 
i n f u s i o n o f m e t h o t r e x a t e d u r i n g 
chemotherapy. Subramaniam et al. 
(2008) had observed that the most used 
d r u g s w e r e d a u n o r u b i c i n 3 0 m g , 
vincristine 1.4 mg, L-asparaginase, 
methotrexate 12 mg. Torres et al (2010) 
had identified doxorubicin, vincristine, 
p r e d n i s o n e , L - a s p a r a g i n a s e a n d 
methotrexateas the most used drugs. 
PelseMielnik (2012) only state that the 
Berlin-Frankfurt-Münster Protocol has 
been used. Mendonça et al. (2012) had 
only also stated that the protocol that has 
been used was the one proposed by 
Brazilian Society of Pediatric Oncology. 
 Chemotherapy treatment may 
be directly toxic and affect the oral 
mucosae by the systemic circulation. 
Besides that, for many times the saliva 
secretion of the used drugs occurs, which 
results in medication exposition in the 
oral cavity. The analysis has been made 
between the buccal alterations incidence 
and the used drugs, and the correlation 
has not been statistically significant. 
Corroborating with our findings, Pinto et 
al. (2006), Subramaniam et al. (2008), 
Torres et al. (2010), Pels & Mielnik (2012), 
Mendonça et al. (2012) had stated that the 
use of the medicine combination on 
chemotherapy cannot be directly 
correlated with the oralmanifestations 
that are present in the individual. 
 However, it is important to 
expose the study of Hsieh et al. (2011), in 
which a research has been developed to 
evaluate the effect of anti-neoplastic 
therapy on the dental development and 
on the salivary function in receptors of 
anti-neoplastic therapy during the 
childhood. They have concluded that the 
children and the teenagers who had 
received high doses of cyclophosphamide 
had a higher risk of developing dental 
disorders. 
CONCLUSIONS 
 In the face of the results, it has 
been concluded that there has not been 
an influence of the chemotherapy agents 
and of their accessories on the oral 
manifestations of acute lymphoid 
leukemic children. However, those 
patients may present some lesion on the 
oral cavity during or after the beginning 
of chemotherapy treatment. The dentist 
surgeon needs to recognize the oral 
manifestations and intervene on the ALL 
patient’s buccal health, contributing and 
helping with his/her treatment. 
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